
    Original Text: FOR DOSE EXPANSION COHORT ONLY: Pathologically confirmed breast cancer with the following features:
* Measurable disease by RECIST 1.1
* ER and PR =< 1% by immunohistochemistry
* Her-2/neu negative (0 or 1+ by immunohistochemistry OR not amplified by CAP/ASCO standards)
* Metastatic or unresectable and locally advanced and not amenable to treatment with curative intent, in the opinion of the enrolling investigator
    Disease/Condition: Breast cancer
    Procedure: none
    Drug: none
    Biomarker: ER < 1%, PR < 1%, HER2 negative
    Computable Rule: Disease is "Breast cancer" AND ER <= 1% is True AND PR <= 1% is True AND HER2 is False

Criterion:
    Patients must have measurable disease per RECIST v1.1

Output:
    Original Text: Patients must have measurable disease per RECIST v1.